2024ASCOMemorial Sloan Kettering Cancer Center (MSK)’s Prof. Wungki Park Unveils Precision Targeting of TF in Pancreatic Cancer, Signaling ADC Drug Innovations [Video]

Introduction: ADC Drug Breakthrough Targets TF in Pancreatic Cancer

CHICAGO, June 12, 2024 /PRNewswire/ — The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago from May 31 to June 4, shone a spotlight on MRG004A, a novel antibody-drug conjugate (ADC) designed to treat advanced solid tumors with high tissue factor (TF) expression. TF, whose levels are significantly elevated in various cancers, particularly in pancreatic cancer, is strongly linked to poor prognosis and metastasis. As a result, TF has emerged as a pivotal target for new therapeutic strategies aimed at enhancing the treatment outcomes of patients with solid tumors. At the conference, a highly anticipated oral presentation focused on the “Phase I/II First-in-Human Study to Evaluate the Efficacy and Safety of TF-ADC MRG004A in Patients with Solid Tumors.” The study was featured in a 15-minute keynote session, standing out as one of only two ADC studies presented in the ASCO Main Session. This recognition underscores the …